
Business & Markets · October 19, 2026
Roche signs Hansoh deal that could exceed $15 billion for cancer-drug programs
Hansoh will lead two preclinical programs through Phase Ia, while Roche gets development rights outside Greater China. The headline figure depends on future milestones and is not guaranteed revenue.
Reporting draws on 3 named sources.






